Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigation of Therapeutic Drug Monitoring of Tacrolimus in Different Age Groups: Results from a Turkish Nationwide Study

Author(s): Murat Caglayan*, Ataman Gonel, Osman Celik, Abdulvahit Sozuer, Mustafa Mahir Ulgu, Naim Ata and Suayip Birinci

Volume 20, Issue 6, 2023

Published on: 03 October, 2022

Page: [718 - 723] Pages: 6

DOI: 10.2174/1570180819666220825122534

Price: $65

conference banner
Abstract

Background: The blood level of tacrolimus (TAC) used for post-transplant immunosuppression should be within the therapeutic index. Geriatric individuals may be at risk of organ rejection because, in this age group, routine drug use is usually disrupted, and the bioavailability of aging-related drugs is decreased.

Objective: The aim of this study was to analyze the age-related variability of blood TAC levels in patients in Turkey.

Methods: In this study, 697,616 patients who underwent TAC measurement in the laboratories of public, private, and university hospitals between 2018 and 2020 were identified from the Health-net database of the Ministry of Health. The results of patients aged ≥65 years were compared with those of patients aged <65 years. The differences between the sexes in the same age group were also examined. Data from the Turkish Ministry of Health National Electronic Database were used to design a multicenter retrospective cohort study.

Results: The study included 697,616 patients. The mean TAC concentration was 7.2 ± 6.25 ng/mL for all the patients, 7.13 ± 6.7 ng/mL for the female patients, and 7.24 ± 5.96 ng/mL for the male patients. A statistically significant difference in TAC concentration was found between men and women in the general population. Groups aged ≥65 years were compared among themselves. A statistically significant decrease in TAC concentration was found only in the age group of 75–79 years (5.63 ± 4.09 ng/mL) of women compared with the men. In all other age groups, the TAC levels of the men were lower.

Conclusion: The proportion of patients with TAC concentrations lower than the therapeutic index was higher in the groups aged ≥65 years. Thus, patients aged ≥65 years may be at risk of organ rejection, as optimum immunosuppression cannot be achieved. In these patients, more frequent drug monitoring and providing training to ensure the compliance of the patient and the patient's relatives in the use of TAC may be recommended.

Keywords: Tacrolimus, elderly, big data, drug analysis, drug monitoring, optimum immunosuppression.

« Previous Next »
Graphical Abstract

[1]
Sandhu, H.; Kaplan, H.J. Clinical Cases in Uveitis E-Book: Differential Diagnosis and Management; Elsevier, 2021.
[2]
Staatz, C.E.; Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet., 2004, 43(10), 623-653.
[http://dx.doi.org/10.2165/00003088-200443100-00001] [PMID: 15244495]
[3]
Peters, D.H.; Fitton, A.; Plosker, G.L.; Faulds, D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs, 1993, 46(4), 746-794.
[http://dx.doi.org/10.2165/00003495-199346040-00009] [PMID: 7506654]
[4]
Gönel, A.; Koyuncu, I. False immunosuppressant measurement by LC-MS/MS method due to radiopaque agents. J. Comb. Chem., 2019, 22(2), 129-134.
[PMID: 31038053]
[5]
Gönel, A.; Koyuncu, I.; Bayraktar, N.; Tayman, C.; Bardakçı, O.; Uzunköy, A.; Guzelcicek, A. Enzyme replacement therapy may affect blood immunosuppressant monitoring. Curr. Pediatr. Rev., 2021, 16(4), 314-319.
[http://dx.doi.org/10.2174/1573396316666200507092858] [PMID: 32379593]
[6]
Staatz, C.; Taylor, P.; Tett, S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol. Dial. Transplant., 2001, 16(9), 1905-1909.
[http://dx.doi.org/10.1093/ndt/16.9.1905] [PMID: 11522877]
[7]
Watt, K.D.; Dierkhising, R.; Heimbach, J.K.; Charlton, M.R. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: An analysis of the scientific registry of transplant recipients database. Liver Transpl., 2012, 18(9), 1029-1036.
[http://dx.doi.org/10.1002/lt.23479] [PMID: 22641474]
[8]
Breitkreutz, J.; Boos, J. Paediatric and geriatric drug delivery. Expert Opin. Drug Deliv., 2007, 4(1), 37-45.
[http://dx.doi.org/10.1517/17425247.4.1.37] [PMID: 17184161]
[9]
Shruthi, R.; Jyothi, R.; Pundarikaksha, H.P.; Nagesh, G.N.; Tushar, T.J. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J. Clin. Diagn. Res., 2016, 10(12), FC40-FC43.
[http://dx.doi.org/10.7860/JCDR/2016/21908.9088] [PMID: 28208878]
[10]
Shah, R.R. Drug development and use in the elderly: Search for the right dose and dosing regimen. Br. J. Clin. Pharmacol., 2004, 58(5), 452-469.
[http://dx.doi.org/10.1111/j.1365-2125.2004.02228.x] [PMID: 15521892]
[11]
Klotz, U. The elderly—A challenge for appropriate drug treatment. Eur. J. Clin. Pharmacol., 2008, 64(3), 225-226.
[http://dx.doi.org/10.1007/s00228-007-0410-5] [PMID: 18071682]
[12]
Przepiorka, D.; Blamble, D.; Hilsenbeck, S.; Danielson, M.; Krance, R.; Chan, K.W. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant., 2000, 26(6), 601-605.
[http://dx.doi.org/10.1038/sj.bmt.1702588] [PMID: 11041564]
[13]
Krenzien, F.; Quante, M.; Heinbokel, T.; Seyda, M.; Minami, K.; Uehara, H.; Biefer, H.R.C.; Schuitenmaker, J.M.; Gabardi, S.; Splith, K.; Schmelzle, M.; Petrides, A.K.; Azuma, H.; Pratschke, J.; Li, X.C.; ElKhal, A.; Tullius, S.G. Age dependent metabolic and immunosuppressive effects of tacrolimus. Am. J. Transplant., 2017, 17(5), 1242-1254.
[http://dx.doi.org/10.1111/ajt.14087] [PMID: 27754593]
[14]
Neto, D.E.; Romano, P.; Triboni, K.A.H.; Ramos, F.; Agena, F.; Ebner, A.R.P.; Altona, M.; Galante, N.Z.; Lemos, B.C.F. Longitudinal pharmacokinetics of tacrolimus in elderly compared with younger recipients in the first 6 months after renal transplantation. Transplantation, 2017, 101(6), 1365-1372.
[http://dx.doi.org/10.1097/TP.0000000000001369] [PMID: 27482958]
[15]
Turnheim, K. Drug therapy in the elderly. Exp. Gerontol., 2004, 39(11-12), 1731-1738.
[http://dx.doi.org/10.1016/j.exger.2004.05.011] [PMID: 15582289]
[16]
Hosohata, K.; Masuda, S.; Katsura, T.; Takada, Y.; Kaido, T.; Ogura, Y.; Oike, F.; Egawa, H.; Uemoto, S.; Inui, K. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab. Dispos., 2009, 37(4), 821-826.
[http://dx.doi.org/10.1124/dmd.108.025833] [PMID: 19139162]
[17]
Scott, L.J.; McKeage, K.; Keam, S.J.; Plosker, G.L. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs, 2003, 63(12), 1247-1297.
[http://dx.doi.org/10.2165/00003495-200363120-00006] [PMID: 12790696]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy